Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing

Abstract

Background: The literature on cervical cancer screening has increasingly recognized the significance of high-risk human papillomavirus (hrHPV) testing as a primary screening method, reflecting a shift from traditional cytological approaches. Literature Review: The implications of HPV vaccination on screening protocols have also been explored, particularly in Europe, where the declining prevalence of HPV necessitates more sensitive screening methods (C. Chrysostomou et al., 2018). The integration of hrHPV testing is seen as not only enhancing sensitivity but also providing cost-effective solutions through longer screening intervals, which can improve patient compliance and reduce healthcare costs (Kyrgiou et al., 2020). In Canada, there is a growing recognition of the need to update cervical cancer screening guidelines to incorporate hrHPV testing, particularly in light of disparities in screening rates among underrepresented populations (Gates et al., 2021). The potential for self-sampling in hrHPV testing presents an innovative approach to increasing screening uptake, especially in low- and middle-income countries where access to healthcare is limited (Lozar et al., 2021). Recent systematic reviews have confirmed the diagnostic accuracy of hrHPV testing, demonstrating its ability to lower the incidence of cervical cancer, particularly among women who were screen-negative at baseline (F. Hamers et al., 2022). However, it is important to note that hrHPV testing may not be suitable for women under 30 due to the higher prevalence of transient infections in this demographic, necessitating the implementation of triage tests to identify persistent infections (Kyrgiou et al., 2020). Conclusion: In conclusion, the literature collectively supports the adoption of hrHPV testing as a primary screening modality for cervical cancer. The advantages of enhanced sensitivity, cost-effectiveness, and the potential for self-sampling highlight a significant paradigm shift in cervical cancer prevention strategies. Ongoing research and policy evaluations will be essential to optimize screening programs and ensure equitable access to cervical cancer prevention efforts worldwide.